AB&B Bio-Tech (02627) disclosed its Monthly Return for the period ended 31 March 2026, confirming that no changes occurred in either its authorised or issued share capital during the month.

Authorised and registered capital remained at RMB 393.44 million, comprising 296.36 million H shares and 97.08 million domestic shares, each with a par value of RMB 1. The issued share structure was unchanged: 296.36 million H shares and 97.08 million domestic shares, with no treasury stock on the company’s balance sheet.

The filing also affirms that the minimum 25 percent public-float requirement under Hong Kong Listing Rules was fully met as at 31 March 2026. No share options, warrants, convertible securities, or other equity-linked instruments were issued, exercised, or outstanding, and there were no share repurchases or other treasury-share movements during the month.

The statement was authorised by Executive Director Li Runxiang and submitted to Hong Kong Exchanges and Clearing Limited on 9 April 2026.